Efficient mucus permeation and tight junction opening by dissociable "mucus-inert" agent coated trimethyl chitosan nanoparticles for oral insulin delivery

被引:204
作者
Liu, Min [1 ]
Zhang, Jian [1 ]
Zhu, Xi [1 ]
Shan, Wei [1 ]
Li, Lian [1 ]
Zhong, Jiaju [1 ]
Zhang, Zhirong [1 ]
Huang, Yuan [1 ]
机构
[1] Sichuan Univ, West China Sch Pharm, Key Lab Drug Targeting & Drug Delivery Syst, Minist Educ, Chengdu 610041, Peoples R China
基金
中国国家自然科学基金;
关键词
Trimethyl chitosan; HPMA copolymers; Oral delivery; Insulin; Mucus layer; Nanoparticles; DRUG DELIVERY; IN-VITRO; POLYMERIC NANOPARTICLES; PROTEIN TRANSDUCTION; CELLULAR UPTAKE; ABSORPTION; MECHANISM; DIFFUSION; PEPTIDES; PENETRATION;
D O I
10.1016/j.jconrel.2015.12.008
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Oral administration of protein drugs is greatly impeded by the lack of drug carriers that can efficiently overcome the absorption barriers of mucosa tissue, which consists of not only epithelium but also a blanket of mucus gel. We herein report a novel self-assembled nanoparticle (NP) platform for oral delivery of insulin by facilitating the efficient permeation through both of these two barriers. The NP possesses a core composed of insulin and trimethyl chitosan (TMC), and a dissociable "mucus-inert" hydrophilic coating of N-(2-hydroxypropyl) methacrylamide copolymer (pHPMA) derivative. The NPs exhibited free Brownian motion and excellent permeability in mucus, which enabled the access of the NP core to the epithelial cell surface underneath the mucus. Moreover, investigation of NP behavior showed that the pHPMA molecules started to dissociate as the NP permeates through mucus, and the TMC NP core was then exposed to facilitate transepithelial transport via paracellular pathway. The pHPMA coating significantly improved transepithelial transport of TMC-based NP and their ability to open tight junctions between the mucus-secreting epithelial cells. Moreover, in diabetic rats, pHPMA coated NPs generated a prominent hypoglycemic response following oral administration, and exhibited a relative bioavailability 2.8-fold higher than that of uncoated TMC-based NPs. Our study provided the evidence of using pHPMA as "mucus-inert" agent to enhance mucus permeation of TMC-based NPs, and validated a novel strategy to overcome the multiple absorption barriers using NP platform with dissociable hydrophilic coating and TMC-based core possessing tight junction-opening ability. (C) 2015 Elsevier B.V. All rights reserved.
引用
收藏
页码:67 / 77
页数:11
相关论文
共 52 条
  • [31] Strategies for effective oral insulin delivery with modified chitosan nanoparticles: A review
    Mukhopadhyay, Piyasi
    Mishra, Roshnara
    Rana, Dipak
    Kundu, Patit P.
    [J]. PROGRESS IN POLYMER SCIENCE, 2012, 37 (11) : 1457 - 1475
  • [32] Cellular Uptake and Fate of PEGylated Gold Nanoparticles Is Dependent on Both Cell-Penetration Peptides and Particle Size
    Oh, Eunkeu
    Delehanty, James B.
    Sapsford, Kim E.
    Susumu, Kimihiro
    Goswami, Ramasis
    Blanco-Canosa, Juan B.
    Dawson, Philip E.
    Granek, Jessica
    Shoff, Megan
    Zhang, Qin
    Goering, Peter L.
    Huston, Alan
    Medintz, Igor L.
    [J]. ACS NANO, 2011, 5 (08) : 6434 - 6448
  • [33] Targetable HPMA copolymer-adriamycin conjugates. Recognition, internalization, and subcellular fate
    Omelyanenko, V
    Kopeckova, P
    Gentry, C
    Kopecek, J
    [J]. JOURNAL OF CONTROLLED RELEASE, 1998, 53 (1-3) : 25 - 37
  • [34] Recombinant protein therapeutics - success rates, market trends and values to 2010
    Pavlou, AK
    Reichert, JM
    [J]. NATURE BIOTECHNOLOGY, 2004, 22 (12) : 1513 - 1519
  • [35] Chitin and chitosan: Properties and applications
    Rinaudo, Marguerite
    [J]. PROGRESS IN POLYMER SCIENCE, 2006, 31 (07) : 603 - 632
  • [36] Preparation, characterization and antibacterial activities of chitosan, N-trimethyl chitosan (TMC) and N-diethylmethyl chitosan (DEMC) nanoparticles loaded with insulin using both the ionotropic gelation and polyelectrolyte complexation methods
    Sadeghi, A. M. M.
    Dorkoosh, F. A.
    Avadi, M. R.
    Saadat, P.
    Rafiee-Tehrani, M.
    Junginger, H. E.
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2008, 355 (1-2) : 299 - 306
  • [37] Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer
    Seymour, Leonard W.
    Ferry, David R.
    Kerr, David J.
    Rea, Daniel
    Whitlock, Maggie
    Poyner, Richard
    Boivin, Christopher
    Hesslewood, Stuart
    Twelves, Christopher
    Blackie, Robert
    Schatzlein, Andreas
    Jodrell, Duncan
    Bissett, Donald
    Calvert, Hilary
    Lind, Mike
    Robbins, Adele
    Burtles, Sally
    Duncan, Ruth
    Cassidy, James
    [J]. INTERNATIONAL JOURNAL OF ONCOLOGY, 2009, 34 (06) : 1629 - 1636
  • [38] Overcoming the Diffusion Barrier of Mucus and Absorption Barrier of Epithelium by Self-Assembled Nanoparticles for Oral Delivery of Insulin
    Shan, Wei
    Zhu, Xi
    Liu, Min
    Li, Lian
    Zhong, Jiaju
    Sun, Wei
    Zhang, Zhirong
    Huang, Yuan
    [J]. ACS NANO, 2015, 9 (03) : 2345 - 2356
  • [39] Biodistribution, pharmacodynamics and pharmacokinetics of insulin analogues in a rat model: Oral delivery using pH-Responsive nanoparticles vs. subcutaneous injection
    Sonaje, Kiran
    Lin, Kun-Ju
    Wey, Shiaw-Pyng
    Lin, Che-Kuan
    Yeh, Tzyy-Harn
    Nguyen, Ho-Ngoc
    HsuA, Chia-Wei
    Yen, Tzu-Chen
    Juang, Jyuhn-Huarng
    Sung, Hsing-Wen
    [J]. BIOMATERIALS, 2010, 31 (26) : 6849 - 6858
  • [40] Lung gene therapy with highly compacted DNA nanoparticles that overcome the mucus barrier
    Suk, Jung Soo
    Kim, Anthony J.
    Trehan, Kanika
    Schneider, Craig S.
    Cebotaru, Liudmila
    Woodward, Owen M.
    Boylan, Nicholas J.
    Boyle, Michael P.
    Lai, Samuel K.
    Guggino, William B.
    Hanes, Justin
    [J]. JOURNAL OF CONTROLLED RELEASE, 2014, 178 : 8 - 17